ישראל - עברית - Ministry of Health

medison pharma ltd - cysteamine as bitartrate - קפסולה קשיחה - cysteamine as bitartrate 150 mg - mercaptamine

ישראל - עברית - Ministry of Health

medison pharma ltd - cysteamine as bitartrate - קפסולה קשיחה - cysteamine as bitartrate 50 mg - mercaptamine

ישראל - עברית - Ministry of Health

medison pharma ltd - cysteamine as bitartrate - קפסולה קשיחה - cysteamine as bitartrate 50 mg - mercaptamine

ישראל - עברית - Ministry of Health

medison pharma ltd - betaine anhydrous - אבקה להכנת תמיסה - betaine anhydrous 1 g/g - betaine

ישראל - עברית - Ministry of Health

medison pharma ltd - mercaptamine as hydrochloride - תמיסה לעין - mercaptamine as hydrochloride 3.8 mg - mercaptamine

ישראל - עברית - Ministry of Health

medison pharma ltd - mercaptamine as hydrochloride - תמיסה לעין - mercaptamine as hydrochloride 3.8 mg - mercaptamine

ישראל - עברית - Ministry of Health

medison pharma ltd - osilodrostat as phosphate - טבליות מצופות פילם - osilodrostat as phosphate 1 mg - osilodrostat

ישראל - עברית - Ministry of Health

medison pharma ltd - osilodrostat as phosphate - טבליות מצופות פילם - osilodrostat as phosphate 10 mg - osilodrostat

ישראל - עברית - Ministry of Health

medison pharma ltd - osilodrostat as phosphate - טבליות מצופות פילם - osilodrostat as phosphate 5 mg - osilodrostat

ישראל - עברית - Ministry of Health

medison pharma ltd - natalizumab - תרכיז להכנת תמיסה לאינפוזיה - natalizumab 300 mg / 15 ml - natalizumab - natalizumab - tysabri is indicated as monotherapy for the treatment of patients with relapsing forms of multiple sclerosis . to delay the accumulation of physical disability and reduce the frequency of clinical exacerbations. the safety and efficacy of tysabri beyond two years are unknown. because tysabri increases the risk of progressive multifocal leukoencephalopathy (pml), an opportunistic viral infection of the brain that usually leads to death or severe disability. tysabri is generally recommended for patients who have had an inadequate response to, or are unable to tolerate, alternate multiple sclerosis therapies. safety and efficacy in patients with chronic progressive multiple sclerosis have not been studied.